78 results about "Hepatic toxicity" patented technology

The present invention relates generally to the method of increasing the oral bioavailability, reducing chemotherapy induced toxicity and side effects, and improving the effectiveness of pharmaceutical agents that are poorly absorbed from the gastrointestinal tract. Specifically, the invention relates to poorly absorbed pharmaceutical drugs and converting them to orotate salts. The orotate salts of the drugs can be dosed at lower doses to provide the efficacy benefits of a higher dose, while reducing the drugs' toxic effects at lower doses. Additionally, the orotate salts of pharmaceutical agents have better clearance and reduce the potential for drug-induced hepatic toxicity. Therefore, an especially useful formulation of the orotate salt of the pharmaceutical agent can provide rapid and consistent action using a lower dose while reducing drug interactions and side-effects.

Methods and compositions for the stabilization of aminotransferase activity of plasma or serum are provided. Such methods will be useful in the accurate determination of tests associated with liver toxicity.

The invention is related to methods of treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases.

A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g / L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.

The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express a hepatic stellate phenotype and cells that express a hepatic sinusoidal endothelial phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of liver deficiency, liver metabolism studies, and liver toxicity studies.

The present invention relates generally to the method of increasing the oral bioavailability, reducing chemotherapy induced toxicity and side effects, and improving the effectiveness of pharmaceutical agents that are poorly absorbed from the gastrointestinal tract. Specifically, the invention relates to poorly absorbed pharmaceutical drugs and converting them to orotate salts. The orotate salts of the drugs can be dosed at lower doses to provide the efficacy benefits of a higher dose, while reducing the drugs' toxic effects at lower doses. Additionally, the orotate salts of pharmaceutical agents have better clearance and reduce the potential for drug-induced hepatic toxicity. Therefore, an especially useful formulation of the orotate salt of the pharmaceutical agent can provide rapid and consistent action using a lower dose while reducing drug interactions and side-effects.

A diagnostic kit containing an anti-dog hemoglobin monoclonal antibody and an application thereof. The invention relates to a monoclonal antibody, and particularly relates to an anti-dog hemoglobin monoclonal antibody. The invention provides a mouse hybridoma cell strain, which is a strain preserved in China general microbiological culture collection center with a preservation number of CGMCC No. 4619. The invention also provides a monoclonal antibody generated by the mouse hybridoma cell strain with a preservation number of CGMCC No. 4619, and a kit containing the monoclonal antibody. The kit provided by the invention has high sensitivity, strong specificity, good accuracy and precision, and good stability, can detect dog hemoglobin in a sample to be detected specifically and sensitively, can exactly evaluate the gastrointestinal toxicity, the hepatic toxicity, the hematopoietic system toxicity, and the like of a medicament, and provides more scientific and accurate evaluation of the nonclinical safety of a medicament.

The invention relates to the use of schisandra fruit in preparing medicament for prevention and abatement of toxic and side effects of antineoplastic drugs including cardiovascular toxicity, liver toxicity, kidney toxicity, or bone marrow depression, or immunological suppression or trichomadesis.

Embodiments of the present invention provide a drug hepatotoxicity prediction method and device, which relate to the technical field of drug prediction. The method comprises: after acquiring the data of the drug to be tested, classifying the data of the drug to be tested according to a preset classifier group to obtain a plurality of initial classification results; and then based on the plurality of initial classification results and the preset voting strategy According to the rule, a classification result is obtained, and the classification result represents the hepatotoxicity of the drug data to be tested. By classifying the drug data through the preset classifier group and voting strategy, the hepatotoxicity of the drug data can be obtained, the prediction efficiency and accuracy can be improved, and the future development needs of the pharmaceutical industry can be adapted. More effective control of development costs.

Methods, formulations and kits for treating and / or protecting against acute liver failure and other hepatotoxicities in an individual employ a combination of a first active agent which replenishes, or decreases a loss of, functional glutathione in the individual, and a second active agent comprising a manganese complex selected from the group consisting of (i) a calcium manganese mixed metal complex of N,N′-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N′-diacetic acid (DPDP) having a molar ratio of calcium to manganese in a range of from 1 to 10, or a pharmaceutically acceptable salt thereof, (ii) a mixture of manganese DPDP (MnDPDP), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing DPDP compound, or (iii) a mixture of manganese pyridoxyl ethylenediamine (MnPLED), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing pyridoxyl ethylenediamine (PLED) compound.

The invention discloses a method for processing rhizoma alismatis. The method includes manufacturing steps of cleaning, slicing, drying, ultraviolet lamp irradiating, braising, microwave drying, packaging and the like. The method has the advantages that the problems of certain hepatic toxicity and renal toxicity of existing rhizoma alismatis in the traditional technological procedures for processing the existing rhizoma alismatis can be solved by the aid of the method; destruction of toxic substances in the rhizoma alismatis can be accelerated by means of ultraviolet lamp irradiation, and accordingly hepatic and renal toxicity of the rhizoma alismatis can be reduced; technologies for processing the rhizoma alismatis are optimized, accordingly, alisol A and alisol B in processed rhizoma alismatis medicinal slices can be easily decocted to seep out, and effects of inducing diuresis, excreting dampness and clearing kidney fire can be enhanced.

The present invention relates to the use of sphingolipids for the preparation of a food item, a food supplement and / or a medicament for the prevention and / or treatment of elevated blood levels of cholesterol and triglycerides related to steatosis and hepatotoxic effects of medicaments and viral infections. In particular, the invention relates to the use of a sphingolipid such as phytosphingosine, sphingosine, sphinganine, ceramide, glycosylceramide and / or sphingomyelin, or a precursor or a derivative of a sphingolipid, or a pharmaceutically acceptable salt thereof, for the prevention and / or treatment of hepatotoxic effects such as hepatic steatosis, fibrosis and / or cirrhosis.

The invention provides a hepatoxic substance sieving and evaluating method based on cell states labeled by fluorescence, which is a sieving and evaluating method combining a hardware / software system. The images are acquired by a fluorescence inverted microscope and a computer in real time, the biological information is processed and visualized, the liner dynamic range width of the living cell ismeasured by combining FDA dyeing, and then the relevant parameters for evaluating the hepatoxic substances are provided. The method is quick, sensitive and economical, and is used for quickly detecting the influence of the sieved sample on cell quantity, forms, migration, apoptasis and the like under the condition of maintaining cell structure and function integrity, accurately carrying out quantitative analysis on the activity of the cell labeled by the fluorescence specialty and detecting the activity change of the cell under the function of the hepatoxic substances. The method has reasonable design. The provided sieving and evaluating system has complete structure, and can be used for sieving and evaluating the hepatoxic substances.

The invention discloses a method for predicting hepatotoxicity caused by drug interaction based on a graph neural network model, which comprises the following steps: establishing a deep learning model for predicting hepatotoxicity caused by drug interaction based on a graph neural network, and predicting hepatotoxicity caused by drug interaction based on the deep learning model, the method comprises the following steps: encoding two drug molecules by using a drug molecule encoder constructed based on a graph neural network, predicting a hepatotoxicity score caused by interaction of the two drugs through a full-connection neural network, and judging whether the combination of the two drugs can cause hepatotoxicity according to the predicted hepatotoxicity score. The method not only reduces the fund and time investment of drug combination preclinical toxicity research and development to a certain extent, but also can accurately predict the drug interaction hepatotoxicity during drug combination, and avoids the injury to the liver of a patient due to combination of a plurality of drugs. Unnecessary medicine combination clinical experiments during development of a new treatment scheme are reduced, and the success rate of the clinical experiments is increased.

The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express a hepatic stellate phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other applications, for treatment of liver deficiencies, liver metabolism studies, and liver toxicity studies, fibrogenic studies, or to support hepatocyte function in co-culture setting.

The invention discloses a method for catalytic hydrogenation reduction of algal toxin in water based on a supported noble metal catalyst, which comprises the following steps: adding the supported noble metal catalyst into a water body containing microcystic toxin, regulating the pH value of the water body to 6.0-9.0, and introducing hydrogen into the water body to perform catalytic hydrogenation reduction reaction. After the reaction is completed, degradation products in the water body do not have hepatotoxicity any more, and the non-toxic effect of the products is achieved. Compared with an existing method for degrading MCLR, the liquid-phase catalytic reduction method provided by the invention can selectively reduce Adda toxic groups of MC-LR, is obvious in toxicity removal, high in MC-LR degradation efficiency and high in speed, and has the advantages of technical feasibility, simplicity in operation, easiness in obtaining materials and no secondary pollution of degradation products.